Tel Aviv University

The State University of New York

Harbor Branch Oceanographic Institution, Inc.

Ramot University Authority for Applied Research and Industrial Development Limited

Other

University of Illinois

The United States of America As Represented by the Department of Health

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Technion Research & Development Foundation Ltd

Pharma Mar, S.a.

State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization

Yoel Kashman

Michael R Boyd

Kirk R Gustafson

James Brislin McMahon

John H Cardellina, Ii

Gordon M Cragg

Richard W Fuller

Ervin Weiss

Eliezer Flescher

Itzhak Ofek

Doel Soejarto

Nathan Sharon

Janina Goldhar

Ilan Spector

Sarath P Gunasekera

Sue S Cross

Dafna Benayahu

May S Lui

Yehuda Benayahu

Nava R Shochet

Amira Rudi

Shiri Shimony

Dorit Reischer

Einat Raz

Ido Sella

Yoram Lanir

Kenneth L Rinehart

Dolores Garcia Gravalos

Peter J McCarthy

Neal S Burres

Frank Koehn

Max Herzberg

H Howard Sun

Anat Elmann

Rivka Ofir

Maria Dolores Garcia Gravalos

Shmuel Carmely

Dina Blasberger

Shinji Tsujii

Marcel Harnik

Gary Gellerman

Michael Schleyer

Shulamit Hirsch

Ganit Koren-Goldshlager

Shinichi Sakemi

M Herzberg

The invention relates to 3,5,4'-trihydroxy-6,7,3&#x2032;-trimethoxyflavone (TIF) and achillolid A in prevention or treatment of Alzheimer's disease as well as other neurodegenerative diseases such as Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), ischemia, immunodeficiency virus-1 (HTV-1)-associated dementia, Lewy body associated dementia, traumatic brain injury (TBI), glioma, epilepsy. Huntington's disease, multiple sclerosis, glaucoma and schizophrenia where neuroinflammation, oxidative stress, glutamate toxicity and amyloid beta toxicity are part of the pathophysiology.

Anti-neuroinflammatory and protective compounds in

The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers.

Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof

A method is disclosed for regenerating connective tissue by administering a scaffold comprising collagen fibers extracted from a soft coral. The length of the soft coral collagen fibers following stretching by about 15% is identical to the length of the fibers prior to stretching.

Method of regenerating connective tissue with a scaffold of coral-derived collagen

An isolated collagen fiber is disclosed, wherein a length of the fiber prior to stretching by about 15%, is identical to a length of the fiber following said stretching by about 15%. The fiber comprises a Nuclear Magnetic Resonance (NMR) spectroscopic profile as shown in FIG. Uses thereof and method of isolating are also disclosed.

Coral-derived collagen and methods of farming same

The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of cancers, especially mammalian cancers.

Jasmonate derivative compounds pharmaceutical compounds and methods of use thereof

Jasmonate derivative compounds, pharmaceuticals compounds and methods of use thereof

A non-food anti-microbial-adhesion and aggregation composition comprising a suitable carrier and an effective amount of an adhesion inhibitory fraction isolated from juice from berries of theplant genus. In an embodiment the anti-aggregation and adhesion fraction is isolated from cranberry juice. It is characterized as being polymeric and having a molecular weight &#x2267;14,000; an elemental analysis of carbon 43-51%, hydrogen 4-5%, no nitrogen, no sulfur and no chlorine; a nuclear magnetic resonance (NMR) line spectrum as set forth in FIGS.A andB; and an ultraviolet spectrum with an absorption peak at 280 nm in neutral or acidic pH solution which is absent in alkali solutions. This fraction exhibits adhesion inhibitory activity against P fimbriated bacteria, oral bacteria and

Anti-microbial-adhesion fraction derived from vaccinium

The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.

Calanolide and related antiviral compounds, compositions, and uses thereof

Compounds of general formula (I), wherein the nature of the group R is not particularly critical and typically takes various forms, include the natural compound halitulin of formula (I) and have antitumor activity.

Cytotoxic alkaloids halitulin

A non-food anti-microbial-adhesion and aggregation composition comprising a suitable carrier and an effective amount of an adhesion inhibitory fraction isolated from juice from berries of the Vaccinium plant genus. In an embodiment the anti-aggregation and adhesion fraction is isolated from cranberry juice. It is characterized as being polymeric and having a molecular weight &gE;14,000; an elemental analysis of carbon 43-51%, hydrogen 4-5%, no nitrogen, no sulfur and no chlorine; a nuclear magnetic resonance (NMR) line spectrum as set forth in FIGS.,A and,B; and an ultraviolet spectrum with an absorption peak at 280 nm in neutral or acidic pH solution which is absent in alkali solutions. This fraction exhibits adhesion inhibitory activity against P fimbriated bacteria, oral bacteria and

Calanolide and related antiviral compounds, compositions, and uses

A non-food oral hygiene composition comprising a suitable carrier and an effective amount of an adhesion inhibitory fraction isolated from juice from berries of the Vaccinium plant genus. In a preferred embodiment the anti-aggregation fraction is isolated from cranberry juice. It is characterized as being polymeric and having a molecular weight .gtoreq.14,000; an elemental analysis of carbon 43-51%, hydrogen 4-5%, no nitrogen, no sulfur and no chlorine; an NMR line spectrum as set forth in FIGS. 2A and 2B; and an ultraviolet spectrum with an absorption peak at 280 nm in neutral or acidic pH solution which is absent in alkali solutions. This fraction exhibits adhesion inhibitory activity against both P fimbriated bacteria and oral bacteria.

Anti-oral-microbial adhesion fraction derived from vaccinium

Three cytotoxic peptides, the known compound Jaspamide and two new peptides, hemiasterlin (Compound 2) and geodiamolide TA (Compound 3), have been isolated from the sponge Hemiasterella minor. The structures of the three were determined by interpreting the NMR and mass spectra. Hemiasterlin (Compound 2) is a novel linear tripeptide embodying two unique, new natural amino acids and geodiamolide TA (Compound 3) is a newly discovered higher homolog of geodiamolides A-F.

Hemiasterlin and geodiamolide TA

Calanolide and related antiretroviral compounds, compositions, and uses

Growing community of inventors

Tel Aviv, Israel

Yoel Kashman